Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as Treatment for Hypoparathyroidism
June 06, 2018 17:35 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, June 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Reports First Quarter 2018 Financial Results
May 30, 2018 16:02 ET
|
Ascendis Pharma A/S
- Continued execution and achievement of planned milestones across three wholly-owned clinical programs in rare endocrine diseases - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN,...
Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30
May 16, 2018 16:20 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, May 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
May 08, 2018 07:00 ET
|
Ascendis Pharma A/S
- TransCon CNP is Company’s Third Product Candidate in Clinic - COPENHAGEN, Denmark, May 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes...
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
May 07, 2018 16:05 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
Ascendis Pharma A/S Announces Upcoming Investor Presentations
April 25, 2018 08:30 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, April 25, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address...
Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer
April 02, 2018 08:30 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, April 02, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address...
Ascendis Pharma A/S Reports Full Year 2017 Financial Results
March 28, 2018 16:01 ET
|
Ascendis Pharma A/S
- Rare Disease Endocrinology Pipeline Advances, with Significant Milestones Anticipated Over the Next Twelve Months - - Conference Call Today at 4:30...
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018
March 19, 2018 07:01 ET
|
Ascendis Pharma A/S
- Baseline demographics of TransCon Growth Hormone phase 3 heiGHt Trial presented - - Multiple ascending dose cohorts from TransCon PTH phase 1 clinical trial reinforced infusion-like profile...
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28
March 16, 2018 07:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, March 16, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...